home / stock / nspr / nspr news

NSPR News and Press, InspireMD Inc. From 03/16/22

Stock Information
Company Name: InspireMD Inc.
Stock Symbol: NSPR
Market: NASDAQ
Website: inspiremd.com
Menu
NSPR NSPR Quote NSPR Short NSPR News NSPR Articles NSPR Message Board
Get NSPR Alerts

News, Short Squeeze, Breakout and More Instantly...
NSPR - InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard(TM) Stent Platform & MicroNet(TM) Portfolio

TEL AVIV, Israel, March 16, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host a Key Opinion Leade...
NSPR - InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q4 2021 Results - Earnings Call Transcript

InspireMD, Inc. (NSPR) Q4 2021 Earnings Conference Call March 8, 2022 08:30 AM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Pr...

NSPR - InspireMD GAAP EPS of -$0.53, revenue of $1.38M

InspireMD press release (NASDAQ:NSPR): Q4 GAAP EPS of -$0.53. Revenue of $1.38M (+762.5% Y/Y). “We enter 2022 with tremendous momentum, anticipating growth of CGuard, continuing pipeline development and advancing the growing body of evidence demonstrating CGuards’s superiority i...

NSPR - InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results

- CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- - Published CGuard Clinical trial results in Journals of the American College of Cardiology - - Established Reimbursement Approval for CGuard from the French National Aut...
NSPR - InspireMD Q4 2021 Earnings Preview

InspireMD (NASDAQ:NSPR) is scheduled to announce Q4 earnings results on Tuesday, March 8th, before market open. The consensus EPS Estimate is -$0.78 (-680.0% Y/Y) and the consensus Revenue Estimate is $1.3M (+712.5% Y/Y). For further details see: InspireMD Q4 2021 Earnings Preview

NSPR - InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

- CGuard ™ Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients - - CREST-2 Trial is sponsored by the National Institute of Neurological Disorders and Stroke (NINDS) and actively engaged at more than 140 stu...

NSPR - InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update

-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET- TEL AVIV, Israel, Feb. 22, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease ...
NSPR - InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor

TEL AVIV, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced the appointment of Adnan Siddiqu...

NSPR - InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)

TEL AVIV, Israel, Jan. 27, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that Marvin Slosman, Chief Executive Officer, is schedul...

NSPR - InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial

TEL AVIV, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that a live case demonstration featuring CGuard™ ...
Previous 10 Next 10